×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Measuring the Impact of Patient Engagement Activities in Medicines R&D: A Way to Sustain the Cultural Change?
Session Chair(s)
Mathieu Boudes, PhD
Patient Engagement Director
Montsouris Consilium, France
Measuring the impact of patient engagement in medicines R&D provides a means of demonstrating effectiveness of the engagement and thus support for sustaining it. In this session, early results of IMI’s PARADIGM, other recent work on assessing value and measuring impact, and their role in supporting sustainability are discussed.
Learning Objective : Describe the IMI PARADIGM Project’s overall goal and objectives for patient engagement (PE), high level project structure and methods, and early results related to measuring PE impact; Identify the benefits of assessing value and measuring impact of PE; Discuss the importance of PE sustainability and the role of metrics in supporting it.
Speaker(s)
Panelist
Nicholas Brooke, MBA
PFMD, Belgium
Executive Director, Patient Focused Medicines Development (PFMD)
Panelist
Debra L. Michaels, MS
DIA, United States
Associate Director, Scientific Programs
Panelist
Lidewij Eva Vat, DrSc, MS
The Synergist, Netherlands
Program Director
Jaye Bea Smalley, MPA
Immunovant, United States
Head of Patient Advocacy
Have an account?